Guinea-Bissau reportedly rejects US-funded newborn hepatitis B vaccine trial
HealthUnverifiedUpdated:
Ars Technica reports that the proposed study, which would have examined alleged nonspecific harms from the hepatitis B vaccine’s newborn dose, was rejected before any doses were given.
Ministers reportedly reaffirm non-acceptance on October 16
Government officials in Guinea-Bissau reportedly formally rejected a proposed clinical trial involving the newborn dose of hepatitis B vaccine. A lead researcher told Ars Technica that the Council of Ministers reaffirmed its non-acceptance on 16 October. She said the study had not started, no vaccines had been administered, and the trial would not move elsewhere.
The proposed US-funded study had not begun, according to a lead researcher; no vaccine doses had been administered.
Guinea-Bissau’s Council of Ministers reportedly reaffirmed that it would not accept the study. The lead researcher said it will not proceed or be moved to another location.
No trial start, vaccine administration, or relocation planned
The reported decision stops a proposed study involving newborns before enrollment or vaccine administration, and the researchers say they have no plan to relocate it.
Sources
- Ars TechnicaUS-backed vaccine trial on babies canceled after international outcryRead source →